Assessing Paysign (PAYS) Valuation After Record Q1 Results And Patient Affordability Shift

Simply Wall St.

May 16

Paysign (PAYS) is back in focus after reporting record first quarter 2026 results, with revenue of US$28.04 million and net income of US$5.44 million, while its patient affordability business became ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2635054246"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635054246\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635054246?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/8032000-choice1-main-header/1585186551780","is_english":true,"pubTime":"2026-05-16 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635054246","market":"sg","top_or_hot":-1,"title":"Assessing Paysign (PAYS) Valuation After Record Q1 Results And Patient Affordability Shift","media":"Simply Wall St.","content":"<div>\n<p>Paysign (PAYS) is back in focus after reporting record first quarter 2026 results, with revenue of US$28.04 million and net income of US$5.44 million, while its patient affordability business became ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pays/paysign/news/assessing-paysign-pays-valuation-after-record-q1-results-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Paysign (PAYS) Valuation After Record Q1 Results And Patient Affordability Shift</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Paysign (PAYS) Valuation After Record Q1 Results And Patient Affordability Shift\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-16 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/diversified-financials/nasdaq-pays/paysign/news/assessing-paysign-pays-valuation-after-record-q1-results-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Paysign (PAYS) is back in focus after reporting record first quarter 2026 results, with revenue of US$28.04 million and net income of US$5.44 million, while its patient affordability business became ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pays/paysign/news/assessing-paysign-pays-valuation-after-record-q1-results-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PAYS","symbol_name":"Paysign Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pays/paysign/news/assessing-paysign-pays-valuation-after-record-q1-results-and","article_id":"2635054246","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/8032000-choice1-main-header/1585186551780"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pays/paysign/news/assessing-paysign-pays-valuation-after-record-q1-results-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635054246","pubTimestamp":1778899389,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Paysign (PAYS) is back in focus after reporting record first quarter 2026 results, with revenue of US$28.04 million and net income of US$5.44 million, while its patient affordability business became the largest contributor.\nSee our latest analysis for Paysign.\nThe share price has been volatile around these earnings, slipping 2.94% on the day and 9.65% over the past week. However, the 90 day share price return of 65.78% and 1 year total shareholder return of 55.89% still point to strong recent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PAYS":"Paysign Inc","BK4227":"交易和支付处理服务","BK4106":"数据处理与外包服务"},"translate_title":"在创纪录的第一季度业绩和患者负担能力转变后评估Paysign(PAY)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAYS":1.5},"content_text":"Paysign (PAYS) is back in focus after reporting record first quarter 2026 results, with revenue of US$28.04 million and net income of US$5.44 million, while its patient affordability business became the largest contributor. See our latest analysis for Paysign. The share price has been volatile around these earnings, slipping 2.94% on the day and 9.65% over the past week. However, the 90 day share price return of 65.78% and 1 year total shareholder return of 55.89% still point to strong recent momentum off a lower base. If Paysign’s move has you thinking about where else growth and risk might be repriced, it can help to scan a broader set of ideas through 19 top founder-led companies With the stock up 65.78% over 90 days yet still trading at a steep discount to the average analyst price target of US$9.95, you have to ask: is Paysign undervalued, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 53.2% Undervalued With Paysign last closing at $5.62 against a widely followed fair value of $12.00, the most popular narrative frames the stock as heavily discounted while hinging on a major shift in where future profit comes from. While analyst consensus expects pharma patient affordability revenue to more than double in 2025, the extraordinary pace of new program wins and deep customer value creation, already surpassing last year's savings for clients just four months into the year, signals the potential for hyper growth at well beyond projected rates, with this segment rapidly overtaking plasma as the main driver of total revenue and margin expansion. Read the complete narrative. Want to see what sits behind that patient affordability story? The narrative leans on steep revenue compounding, rising margins and a richer earnings base driving that $12.00 fair value. Result: Fair Value of $12.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside story can crack if plasma related revenue continues to fall or if tighter regulation squeezes interchange fees and pushes margins lower than analysts expect. Find out about the key risks to this Paysign narrative. Another Way To Look At Paysign’s Valuation The narrative pegs fair value at $12.00, yet Paysign currently trades on a P/E of 30.2x versus a fair ratio of 20.6x and a peer average closer to 17x. That richer multiple can point to valuation risk if growth or margins fall short, so which story do you think the market is really paying for? To see how that richer P/E compares with what the numbers suggest the ratio could move toward, take a closer look at our breakdown of Paysign’s valuation drivers through See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:PAYS P/E Ratio as at May 2026Next Steps With the bullish and cautious takes laid out, the real question is where you land. Review the numbers, weigh the trade offs, and then check the 2 key rewards and 1 important warning sign. Looking for more investment ideas? If Paysign has sharpened your focus, do not stop here. The next move could come from finding a stock that fits your goals even better.  Target income potential by checking out 12 dividend fortresses that might suit a portfolio built around regular cash returns. Hunt for quality at a discount by scanning screener containing 22 high quality undiscovered gems before the crowd starts paying attention. Dial up resilience in your portfolio by assessing 66 resilient stocks with low risk scores that aim to keep volatility in check.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}